United Therapeutics (NASDAQ: UTHR) reported Q4 EPS of $7.70, $0.60 better than the analyst estimate of $7.10. Revenue for the quarter came in at $790.2 million versus the consensus estimate of $815.24 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.